Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

63 results about "Plasminogen activator" patented technology

Plasminogen activators are serine proteases that catalyze the activation of plasmin via proteolytic cleavage of its zymogen form plasminogen. Plasmin is an important factor in fibrinolysis, the breakdown of fibrin polymers formed during blood clotting. There are two main plasminogen activators: urokinase (uPA) and tissue plasminogen activator (tPA). Tissue plasminogen activators are used to treat medical conditions related to blood clotting including embolic or thrombotic stroke, myocardial infarction, and pulmonary embolism.

Targeted drug and preparation method therefor and use thereof

Provided are a targeted drug and a preparation method therefor and the use thereof. The targeted drug comprises a tissue-type plasminogen activator and a targeting peptide. Thrombus-targeting modification is directly performed on thrombolytic drug rtPA, which has the widest clinical application, by means of a chemical method. The defects of rtPA in terms of a narrow therapeutic time window, a high medication dosage and a high hemorrhage risk are significantly improved. The preparation process is simple and controllable, and the materials required for the preparation are readily available and cost-effective. The toxic effects and degradation problems of materials such as compounds are eliminated. In addition, the treatment process does not require other instruments and devices, which makes the clinical transformation and use of the thrombus-targeting rtPA possible.
Owner:THE GBA NAT INST FOR NANOTECHNOLOGY INNOVATION

T-PA and PAI-1 pseudo compound based on bispecific functional antibody skeleton, construction method and determination kit

The invention discloses a t-PA and PAI-1 pseudo compound based on a bispecific functional antibody skeleton, a construction method and a determination kit, the pseudo compound takes a bifunctional antibody as the skeleton, a tissue-type plasminogen activator t-PA and a tissue-type plasminogen activator inhibitor PAI-1 are used for replacing two variable region arms in a natural antibody structure, and the t-PA and PAI-1 pseudo compound is prepared by using the bifunctional antibody as the skeleton. The protein takes an antibody constant region as a support skeleton, and a tissue type plasminogen activator t-PA and a tissue type plasminogen activator inhibitor PAI-1 are respectively arranged at the Y-type top of the antibody. The tissue-type plasminogen activator t-PA and the tissue-type plasminogen activator inhibitor PAI-1 are constructed into the pseudo-complex in a ratio of 1: 1, and a kit using the pseudo-complex as a freeze-drying calibrator or reference has the characteristics of high sensitivity, good stability and difficulty in interference.
Owner:HANGZHOU FUSHENG BIOTECHNOLOGY CO LTD

Methods for discriminating hemorrhagic stroke from ischemic or mimic stroke using TPA as biomarker

PCT designated stage expiredWO2024240827A1Disease diagnosisBiological testingBlood flowBlood plasma
Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute ischemic stroke is prompt restoration of blood flow to regions of brain that are ischemic but not yet infarcted. Based on this, the inventors compare the plasma concentration of total tPA (antigenic: active + PAI-1 bound) in patients with acute ischemic stroke before any treatment with those in a healthy control group, to evaluate the interest of tPA as a potential diagnostic biomarker in the acute phase of ischemic stroke. In particular, the present invention relates to method for discriminating at early stage an hemorrhagic stroke from an ischemic stroke or a mimic stroke in a subject in need thereof, comprising the steps of i) determining in a blood sample obtained from the said subject the level of tissue-type plasminogen activator (tPA), ii) comparing the level determined in step i) with a reference value and iii) concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is higher than the reference value is predictive of a risk of having or developing an ischemic stroke or a mimic stroke or concluding when the level of tissue-type plasminogen activator (tPA) determined at step i) is lower than the reference value is predictive of a risk of having or developing a hemorrhagic stroke
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Positron emitting radionuclide labeled peptides for human uPAR PET imaging

There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.
Owner:CURASIGHT APS

Tissue-plasminogen activator coated catheter with hydrogel-controlled elution

PCT designated stage expiredWO2024253865A1Pharmaceutical containersCatheterThrombusAntithrombotic
A thrombo-resistant catheter includes a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an intraluminal surface and an extraluminal surface, and the hydrogel coating is disposed on the intraluminal surface and / or the extraluminal surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt.% to about 1 wt.% tissue plasminogen activator. The hydrogel coating may be made of a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide-based hydrogels. Presently preferred natural hydrogels include hyaluronic acid-based hydrogels. The hydrogel coating reacts in the presence of a physiological fluid to absorb water and elute the thrombolytic agent. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluid include interstitial fluid and blood.
Owner:BECTON DICKINSON & CO

Substrates and other cleavable moieties for matriptase and u-plasminogen activator and methods of use thereof

To provide methods of identifying new substrates for proteases and methods of using these substrates in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention relates generally to: polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA); activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator; and methods of making these polypeptides that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and methods of use in a variety of therapeutic, diagnostic and prophylactic indications.SELECTED DRAWING: Figure 4A
Owner:CYTOMX THERAPEUTICS INC

Tissue-plasminogen activator coated catheter with hydrogel-controlled elution

A thrombo-resistant catheter includes a hydrogel coating containing a thrombolytic agent. The thrombolytic agent may be a lyophilized tissue plasminogen activator. The catheter has an intraluminal surface and an extraluminal surface, and the hydrogel coating is disposed on the intraluminal surface and / or the extraluminal surface. The hydrogel coating may have a thickness in the range of about 50 nm to about 150 nm. The hydrogel coating may contain from about 0.1 wt. % to about 1 wt. % tissue plasminogen activator. The hydrogel coating may be made of a synthetic hydrogel or a natural hydrogel. Presently preferred synthetic hydrogels include polyacrylamide-based hydrogels. Presently preferred natural hydrogels include hyaluronic acid-based hydrogels. The hydrogel coating reacts in the presence of a physiological fluid to absorb water and elute the thrombolytic agent. The hydrogel controls elution of the thrombolytic agent. Examples of physiological fluid include interstitial fluid and blood.
Owner:BECTON DICKINSON & CO

Recombinant tissue plasminogen activator (TPA) fragments and uses thereof

PendingCN121419989APeptide/protein ingredientsMicroencapsulation basedRecombinant tissue plasminogen activatorPLG - Plasminogen
The present technology relates to recombinant polypeptides comprising tissue-type plasminogen activator (tPA) fragments or nucleotides encoding said recombinant polypeptides and their use for the treatment of cardiovascular diseases. In some embodiments, the tPA fragment comprises a kringle 2 domain of the tPA.
Owner:VERCETTI BLOOD RESEARCH FOUNDATION +1

A pharmaceutical composition for treating acute ischemic stroke and use thereof

PendingCN122272778AEnhance recanalization stabilityStrong specificityBlood flowDepressant
This invention relates to a pharmaceutical composition and its application for treating acute ischemic stroke. The pharmaceutical composition for treating acute ischemic stroke comprises separately packaged tissue-type plasminogen activator citPA5 and a platelet aggregation inhibitor. Its beneficial effects include significantly improving cerebral blood flow recovery, shortening thrombolysis time, reducing infarct volume, and improving neurological function without increasing the risk of bleeding, demonstrating a good synergistic thrombolytic effect.
Owner:FUZHOU UNIV

Targeting PAI-1 thrombolytic peptide and application thereof

The invention discloses a PAI-1 protein targeting peptide compound (called P peptide for short) with a thrombus dissolving effect and application thereof, and belongs to the field of biological medicine. The PAI-1 targeted thrombolytic polypeptide compound comprises P1, P2, P3 and P4, and is characterized in that the compound is derived from a core structure 'X-Asp-Glu-Leu-Cys-X-Tyr-Tyr-X-X-Cys-X' (cyclization is performed through a disulfide bond between Cys, and X represents any type of amino acid), and the compound can be specifically bound with a key binding site of PAI-1. The polypeptide can significantly reduce the inhibitory effect of PAI-1 on plasminogen activators (tPA, uPA), enhance the activity of a fibrinolytic system, and generate in-vivo and in-vitro thrombolysis effects. The polypeptide compounds P1, P2, P3 and P4 not only have a thrombolysis effect, but also can reduce the expression level of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6 and the like), which shows that the polypeptide compounds also have an anti-inflammatory effect. In conclusion, the polypeptide compound can be used for preparing a PAI-1 antagonist, a thrombolytic agent and an anti-inflammatory agent related to thrombus.
Owner:HAINAN UNIV

Urokinase-type plasminogen activator receptor (UPAR)-PET / CT in neuroendocrine tumors

The present invention relates to a positron emitting imaging agent for prognostic use in patients with neuroendocrine tumors (NENs) undergoing PET imaging for cancer, said imaging agent comprising a uPAR binding peptide linked to the radionuclide 68Ga or 64Cu via the chelators NOTA or DOTA. The present invention also relates to a composition comprising a radiopharmaceutical for use in treating or alleviating neuroendocrine tumors (NENs) in a subject, said radiopharmaceutical comprising a radionuclide and a uPAR binding peptide. Figure 4A will be published together with the abstract.
Owner:CURASIGHT APS

Analog of plasminogen activator and application thereof

The invention belongs to the technical field of medicines, and particularly relates to an analogue of a cysteine zymogen activator (a PAC-1 analogue containing a carvone structure) and application of the analogue in cancer treatment. The invention relates to an analogue of a cysteaspase-3 activator, which is a PAC-1 analogue containing a carvone structure as shown in a formula I. The PAC-1 analogue disclosed by the invention is obtained by retaining structures such as piperazine ring and hydrazide, introducing a monoterpenoid carvone and carrying out structural modification on benzene rings on two sides, and a novel procaspase-3 activator is developed. The derivatives have stronger physiological activity. Pharmacological tests prove that the PAC-1 analogue can inhibit proliferation of various tumor cells and has good anti-cancer activity, and the preparation method of the PAC-1 analogue is simple, feasible and easy to operate.
Owner:SHENYANG PHARMA UNIV

Modified urokinase-type plasminogen activator polypeptides and methods of use

Provided are modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and / or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
Owner:VERTEX PHARMACEUTICALS INC

Immune biosensor for human tissue plasminogen activator antigen

The invention discloses an immune biosensor of a human tissue plasminogen activator antigen, and designs a compound for modifying the immune sensor, a compound solution is dropwise added on the surface of an electrode of the immune biosensor by adopting a dispensing method to form a compound film, and then an aldehyde group is introduced into the solution to modify the surface of the film, so that the immune biosensor is obtained. An aldehyde group is introduced to be combined with a to-be-detected object antibody. NPC, MWCNTs and AuNP are dispersed in a chitosan solution, the electroactivity of an electrode interface is improved, the effective area of electrochemical reaction is increased, the sensitivity of the electrode is improved, and large-range active sites are provided while electrochemical signals are increased; the linear range of the immunosensor is relatively large, and human tissue plasminogen activator antigen detection in a normal concentration range can be realized.
Owner:HEFEI JUXUANMIAN HEALTH TECH CO LTD

Plasminogen for use in treating and preventing lung dysfunction

The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.
Owner:PREVIPHARMA CONSULTING GMBH

Novel soluble urokinase-type plasminogen activator receptor (suPAR) binding molecules and uses thereof

Novel urokinase-type plasminogen activator receptor (uPAR) binding molecules and soluble urokinase-type plasminogen activator receptor (suPAR) binding molecules and methods of their use are disclosed.
Owner:WALDEN BIOSCIENCES INC

Antibodies for treating neurological and neurovascular disorders

The present disclosure provides humanized anti-GluN1 receptor antibodies and antigen-binding fragments or derivatives thereof, which are effective in inhibiting the deleterious effects of tissue-type plasminogen activator (t-PA) mediated by N-methyl-D- aspartate (NMDA) receptors, as well as pharmaceutical compositions and medical uses thereof, particularly for the treatment of neurological, neurovascular or neurodegenerative disorders, such as stroke, multiple sclerosis, Parkinson' s disease, and others.
Owner:LYS THERAPEUTICS

Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase

Provided herein are methods for safe and effective thrombolysis in therapy for human subjects with symptoms of a potential stroke or acute myocardial infarction (“AMI”) using a sequential administration of a low dose bolus of human tissue plasminogen activator (“tPA”) followed by an infusion of a mutant form of human pro-urokinase (“proUK”).
Owner:THROMBOLYTIC SCIENCE INTERNATIONAL LLC

Urokinase-type plasminogen activator receptor (UPAR)-pet / CT in neuroendocrine neoplams

The present invention relates to positron-emitting imaging agents for use in the prognosis of a neuroendocrine neoplasm (NEN) patient in by PET imaging of the cancer, wherein said imaging agent comprises a uPAR binding peptide coupled via the chelating agent NOTA or DOTA to the radionuclide 68Ga or 64Cu. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a neuroendocrine neoplasm (NEN) in a subject, wherein said radiopharmaceutical comprises a radionuclide and a uPAR binding peptide.
Owner:CURASIGHT APS

Urokinase-type plasminogen activator receptor (UPAR)-pet / CT in brain tumours

The present invention relates to positron-emitting imaging agents for use in the prognosis of brain tumours in a patient by PET imaging of the cancer, wherein said imaging agent comprises an uPAR binding peptide coupled to a radionuclide. The invention also relates to compositions comprising a radiopharmaceutical for use in the treatment or alleviation of a brain tumour in a subject, wherein said radiopharmaceutical comprises a radionuclide and an uPAR binding peptide.
Owner:CURASIGHT APS

Nano drug delivery system as well as preparation method and application thereof

The invention discloses a nano drug delivery system and a preparation method and application thereof.The nano drug delivery system comprises nano particles, a platelet membrane, a tissue-type plasminogen activator and a thrombin specific aptamer, the nano particles are at least partially coated with the platelet membrane, and the thrombin specific aptamer is at least partially coated with the tissue-type plasminogen activator. The tissue-type plasminogen activator and the thrombin specific aptamer are connected to the platelet membrane. The nano drug delivery system disclosed by the invention has good targeting property, a rapid thrombolysis effect and a local anticoagulation effect, and is beneficial to avoiding secondary coagulation and reembolism risks.
Owner:SHENZHEN SECOND PEOPLES HOSPITAL (SHENZHEN INST OF TRANSLATIONAL MEDICINE)

Protein biomarker for disease associated with contact activation system

To provide a method and a kit for analyzing a biological sample obtained from a subject having, suspected to have, or at the risk for a disease associated with a contact activation system.SOLUTION: There is provided a method for analyzing a sample including: (i) preparing a biological sample (for example, serum sample or plasma sample) obtained from a subject (human subject) having, suspected to have, or at the risk for a disease associated with a contact activation system; and measuring the level of a set of biomarkers including at least one type of protein selected from a table 1, in which when the set of biomarkers consists of one type of protein, the protein is not C4, plasma prekallikrein, thrombin, a tissue-type plasminogen activator (tPA), and heat shock protein 90.SELECTED DRAWING: Figure 1
Owner:TAKEDA PHARMA CO LTD

Screening of active ingredients of Euphorbiaceae plants for hemostatic activity and its application

ActiveCN117110454BOrganic active ingredientsComponent separationUrokinase Plasminogen ActivatorBULK ACTIVE INGREDIENT
The application discloses screening of hemostatic active components in Euphorbiaceae plants and application thereof, and based on ultrafiltration mass spectrometry technology and taking urokinase-type plasminogen activator as a key target enzyme, a hemostatic active component, breynol, of cyclopentanone isocoumarins in Euphorbiaceae plants is screened for the first time. The breynol shows strong specific binding to urokinase plasminogen activator, and the activity inhibition (IC 50 ) of the breynol to the urokinase plasminogen activator is 0.187±0.000 mM, which is superior to that of the positive control tranexamic acid (IC 50 =2.425±0.001 mM). The breynol is reported for the first time in the research of hemostatic activity of Euphorbiaceae plants, and can be used for preparation of daily or clinical hemostatic drugs.
Owner:WUHAN BOTANICAL GARDEN CHINESE ACAD OF SCI